Table 2. Characteristics of included studies investigating ILD patients with versus without poor outcomes.
| With poor outcomes | Without poor outcomes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author, Country, Year | Study design | Disease | HR/RR/0R (95%CI) | N. | Male (%) | Mean age | NLR (Mean ± SD) | N. | Male (%) | Mean age | NLR (Mean ± SD) | Poor outcomes | NOS |
| Achaiah, U.K., 2022 [10] | cohort | IPF | 1.31 (1.16–1.48) | 53 | 39 (73.6) | 74.4 | 3.1559±1.6155 | 62 | 49 (79.0) | 74.8 | 2.6366±1.2751 | FVC decline ≥10%/ year | 8 |
| Chen, China, 2022 [9] | cohort | IPF | 1.019 (1.001–1.037)‡ | 161 | 127 (78.6) | 68.45 | 8.18 ± 11.60 | 117 | 93 (79.5) | 67.62 | 4.49 ± 4.76 | Death | 9 |
| García-Núñez, Spain, 2022 [8] | case-control | silicosis | NR | 38 | 38 (100) | 41 | 2.7±1.5 | 53 | 53 (100) | 40.1 | 2.4±1 | Progress massive fibrosis | 6 |
| Paliogiannis, Italy. 2020 [16] | case-control | COVID-19 | NR | 9 | NR | NR | 15.545±16.0941 | 21 | NR | NR | 6.0354±7.2348 | Death | 7 |
| Ruta, Romania, 2020 [15] | case-control | IPF/CTD | NR | 6 | NR | NR | 2.3217±0.6576 | 36 | NR | NR | 2.9103±1.2149 | Death | 7 |
| Shirakashi, Japan, 2020 [33] | cohort | DM | NR | 13 | 5 (38.5) | 62 | 8.5505±7.7242 | 25 | 6 (24) | 45 | 3.7284±1.8867 | Progress hypoxemia | 6 |
| So, China, 2022 [6] | cohort | DM | 1.674 (0.710–3.948) | 47 | 21 (44.7) | 56.5 | 8.4±6.4 | 69 | 30 (43.5) | 49.6 | 5.9±4.5 | Progressive dyspnoea and radiological worsen | 8 |
| Achaiah, U.K., 2022 [31] | cohort | ILD | 1.07 (1.05–1.09) | 183 | NR | NR | NR | 1076 | NR | NR | NR | Death | 8 |
| Mikolasch, U.K., 2022 [7] | cohort | IPF | 2.04 (1.09–3.81) | 533 | NR | NR | NR | 466 | NR | NR | NR | Death or transplant | 6 |
| Saku, Japan, 2021 [12] | cohort | RA | 1.010 (0.885–1.118) | 22 | NR | NR | NR | 50 | NR | NR | NR | Death | 8 |
| Touman, Saudi Arabia, 2022 [30] | case-control | COVID-19 | 5.928 (1.243–28.273)‡ | 19 | 14 (73.7) | 59.74 | NR | 19 | 10 (52.6) | 54.36 | NR | Persistent radiological worsen | 8 |
| Zhang, China, 2021 [11] | cohort | PSS | 1.43 (1.12–2.57)§ | 35 | NR | NR | NR | 182 | NR | NR | NR | Death | 6 |
| Zou, China, 2015 [32] | cohort | DM | 1.090 (0.956–1.242) | 13 | 5 (38.5) | 52 | 12.9745±6.7275 | 24 | 13 (54.2) | 51 | 6.9818±7.6442 | Death | 8 |
‡OR
§RR
NLR,neutrophil-to-lymphocyte ratio;ILD,interstitial lung diseases;N.,number;SD,standard deviation;NOS,the modified Newcastle-Ottawa Quality Assessment Scale;NR,no report;OR,odds ratio;RR, relative risk;HR,hazard ratio;RA,rheumatoid arthritis;DM,dermatomyositis;IPF, idiopathic pulmonary fibrosis; CTD,connective tissue diseases;PSS,primary Sjogren’s syndrome;FVC,Forced vital capacity.